CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Haloperidol

氟哌啶醇 杂质对照品Haloperidol Impurities

EP32 个杂质条目32 impurity entries

本页汇总 氟哌啶醇 的 32 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 32 impurity reference standards of Haloperidol with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 氟哌啶醇(Haloperidol)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesBreaking barriers in pharmaceutical analysis: Streamlined UV spectrometric quantification and stability profiling of haloperidol and methylparaben in liquid formulations
    Analytical biochemistry · 2024 · Djilali K et al.  ·  PMID 39089362  ·  DOI
  2. 杂质研究Impurity studiesSeparation and determination of haloperidol, parabens and some of their degradation products by micellar electrokinetic chromatography
    Journal of chromatography. A · 2000 · Driouich R et al.  ·  PMID 11153952  ·  DOI
  3. 杂质研究Impurity studiesDensitometric determination of impurities in pharmaceuticals. Part VI. Determination of 4,4-bis[4-(p-chlorophenyl)- 4-hydroxypiperidino]butyrophenone in haloperidol
    Acta poloniae pharmaceutica · 2000 · Krzek J, Maślanka A  ·  PMID 10846793
  4. 分析方法Analytical MethodsDevelopment and Validation of a Stability-Indicating High-Performance Liquid Chromatography Method Coupled With a Diode Array Detector for Quantifying Haloperidol in Oral Solution Using the Analytical Quality-by-Design Approach
    Journal of separation science · 2025 · Junkert AM et al.  ·  PMID 39740124  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisIncreased synthesis of neurokinin B and enkephalin after chronic haloperidol treatment
    Regulatory peptides · 1993 · Marksteiner J et al.  ·  PMID 8210498  ·  DOI

氟哌啶醇 —— 原料药与杂质对照品Haloperidol — drug substance & impurities

共 33 个条目(含原料药本体)33 items incl. the drug substance
Haloperidol structure
EP原料药 APIAPI
氟哌啶醇Haloperidol
Haloperidol
CAS No.52-86-8
Chemical FormulaC21H23ClFNO2
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 1 (Haloperidol EP Impurity A) structure
EPA
氟哌啶醇杂质1 (氟哌啶醇EP杂质A)Haloperidol Impurity 1 (Haloperidol EP Impurity A)
Haloperidol Impurity 1 (Haloperidol EP Impurity A)
CAS No.3109-12-4
Chemical FormulaC21H24FNO2
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 2 (Haloperidol EP Impurity B) structure
EPB
氟哌啶醇杂质2 (氟哌啶醇EP杂质B)Haloperidol Impurity 2 (Haloperidol EP Impurity B)
Haloperidol Impurity 2 (Haloperidol EP Impurity B)
CAS No.1391052-53-1
Chemical FormulaC21H23ClFNO2
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 3 (Haloperidol EP Impurity C) structure
EPC
氟哌啶醇杂质3 (氟哌啶醇EP杂质C)Haloperidol Impurity 3 (Haloperidol EP Impurity C)
Haloperidol Impurity 3 (Haloperidol EP Impurity C)
CAS No.1391052-87-1
Chemical FormulaC23H27ClFNO2
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 4 (Haloperidol EP Impurity D) structure
EPD
氟哌啶醇杂质4 (氟哌啶醇EP杂质D)Haloperidol Impurity 4 (Haloperidol EP Impurity D)
Haloperidol Impurity 4 (Haloperidol EP Impurity D)
CAS No.67987-08-0
Chemical FormulaC32H36Cl2N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 5 (Haloperidol EP Impurity E) structure
EPE
氟哌啶醇杂质5 (氟哌啶醇EP杂质E)Haloperidol Impurity 5 (Haloperidol EP Impurity E)
Haloperidol Impurity 5 (Haloperidol EP Impurity E)
CAS No.1391054-69-5
Chemical FormulaC27H27ClFNO2
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 6 (Haloperidol EP Impurity F) structure
EPF
氟哌啶醇杂质6 (氟哌啶醇EP杂质F)Haloperidol Impurity 6 (Haloperidol EP Impurity F)
Haloperidol Impurity 6 (Haloperidol EP Impurity F)
CAS No.1391052-67-7
Chemical FormulaC27H27ClFNO2
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 7 structure
7
氟哌啶醇杂质7Haloperidol Impurity 7
Haloperidol Impurity 7
CAS No.34104-67-1
Chemical FormulaC21H25ClFNO2
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 8 structure
8
氟哌啶醇杂质8Haloperidol Impurity 8
Haloperidol Impurity 8
CAS No.185626-66-8
Chemical FormulaC21H22ClNO2
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 9 (Dehydrate Haloperidol) structure
9
氟哌啶醇杂质9 (癸氟哌啶醇)Haloperidol Impurity 9 (Dehydrate Haloperidol)
Haloperidol Impurity 9 (Dehydrate Haloperidol)
CAS No.52669-92-8
Chemical FormulaC21H21ClFNO
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 10 structure
10
氟哌啶醇杂质10Haloperidol Impurity 10
Haloperidol Impurity 10
CAS No.73206-04-9
Chemical FormulaC10H11FO2
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 11 structure
11
氟哌啶醇杂质11Haloperidol Impurity 11
Haloperidol Impurity 11
CAS No.61668-02-8
Chemical FormulaC10H9FO
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 12 structure
12
氟哌啶醇杂质12Haloperidol Impurity 12
Haloperidol Impurity 12
CAS No.1797130-89-2
Chemical FormulaC36H43ClFNO3
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 13 structure
13
氟哌啶醇杂质13Haloperidol Impurity 13
Haloperidol Impurity 13
CAS No.57390-39-3
Chemical FormulaC12H16ClFO2
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 14 structure
14
氟哌啶醇杂质14Haloperidol Impurity 14
Haloperidol Impurity 14
CAS No.1312131-45-5
Chemical FormulaC12H22ClNO3
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 15 structure
15
氟哌啶醇杂质15Haloperidol Impurity 15
Haloperidol Impurity 15
CAS No.772-31-6
Chemical FormulaC10H9FO
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 16 structure
16
氟哌啶醇杂质16Haloperidol Impurity 16
Haloperidol Impurity 16
CAS No.3110-52-9
Chemical FormulaC10H10ClFO
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 17 structure
17
氟哌啶醇杂质17Haloperidol Impurity 17
Haloperidol Impurity 17
CAS No.235109-63-4
Chemical FormulaC16H22ClNO3
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 19 structure
19
氟哌啶醇杂质19Haloperidol Impurity 19
Haloperidol Impurity 19
CAS No.163209-96-9
Chemical FormulaC16H22BrNO3
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 20 structure
20
氟哌啶醇杂质20Haloperidol Impurity 20
Haloperidol Impurity 20
CAS No.144947-47-7
Chemical FormulaC12H12ClNO2
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 21 structure
21
氟哌啶醇杂质21Haloperidol Impurity 21
Haloperidol Impurity 21
CAS No.2325953-74-8
Chemical FormulaC18H17Cl2NO2
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 22 structure
22
氟哌啶醇杂质22Haloperidol Impurity 22
Haloperidol Impurity 22
CAS No.30005-58-4
Chemical FormulaC11H12ClN
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 22  Hydrochloride structure
22
氟哌啶醇杂质22 盐酸盐Haloperidol Impurity 22 Hydrochloride
Haloperidol Impurity 22 Hydrochloride
CAS No.51304-61-1
Chemical FormulaC11H12ClN·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 23 structure
23
氟哌啶醇杂质23Haloperidol Impurity 23
Haloperidol Impurity 23
CAS No.148406-51-3
Chemical FormulaC21H23ClFNO3
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 28 structure
28
氟哌啶醇杂质28Haloperidol Impurity 28
Haloperidol Impurity 28
CAS No.2929289-53-0
Chemical FormulaC21H24ClNO3
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 29 structure
29
氟哌啶醇杂质29Haloperidol Impurity 29
Haloperidol Impurity 29
CAS No.660844-75-7
Chemical FormulaC21H23ClFNO
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 31 structure
31
氟哌啶醇杂质31Haloperidol Impurity 31
Haloperidol Impurity 31
CAS No.34104-51-3
Chemical FormulaC21H21ClFNO3
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 37 structure
37
氟哌啶醇杂质37Haloperidol Impurity 37
Haloperidol Impurity 37
CAS No.56108-25-9
Chemical FormulaC18H20ClNO
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 38 structure
38
氟哌啶醇杂质38Haloperidol Impurity 38
Haloperidol Impurity 38
CAS No.16332-18-6
Chemical FormulaC18H20BrNO
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 39 structure
39
氟哌啶醇杂质39Haloperidol Impurity 39
Haloperidol Impurity 39
CAS No.231958-20-6
Chemical FormulaC18H18ClN
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 39 Hydrochloride structure
39
氟哌啶醇杂质39 盐酸盐Haloperidol Impurity 39 Hydrochloride
Haloperidol Impurity 39 Hydrochloride
CAS No.73330-81-1
Chemical FormulaC18H18ClN·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 42 structure
42
氟哌啶醇杂质42Haloperidol Impurity 42
Haloperidol Impurity 42
CAS No.40064-34-4
Chemical FormulaC5H11NO2·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Haloperidol Impurity 43 structure
43
氟哌啶醇杂质43Haloperidol Impurity 43
Haloperidol Impurity 43
CAS No.61191-90-0
Chemical FormulaC12H14ClFO
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

氟哌啶醇 —— 研究文献与合成路线Haloperidol — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 氟哌啶醇 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Haloperidol. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Determination and degradation study of haloperidol by high performance liquid chromatography
    Trabelsi H, Bouabdallah S, Bouzouita K, et al. · Journal of pharmaceutical and biomedical analysis · 2002 · 被引 14cited 14
  2. Reaction of haloperidol with 5-(hydroxymethyl)-2-furfuraldehyde, an impurity in anhydrous lactose
    Janicki CA, Almond HR · Journal of pharmaceutical sciences · 1974 · 被引 13cited 13
  3. Densitometric determination of impurities in pharmaceuticals. Part VI. Determination of 4,4-bis[4-(p-chlorophenyl)- 4-hydroxypiperidino]butyrophenone in haloperidol
    Krzek J, Maślanka A · Acta poloniae pharmaceutica · 2000 · 被引 6cited 6
  4. Degradation products of irradiated haloperidol: implications for the development of an implantible delivery system
    Booker J · Die Pharmazie · 1988
  5. Studies on the application of integrated gas chromatography-mass spectrometry in drug purity control. Impurities in clofibrate, norethindrone, methandienone, haloperidol and meladrazine
    Diding E, Sandström H, Ostelius J, et al. · Acta pharmaceutica Suecica · 1976
  6. Breaking barriers in pharmaceutical analysis: Streamlined UV spectrometric quantification and stability profiling of haloperidol and methylparaben in liquid formulations
    Djilali K, Maachi R, Mesbah ZA, et al. · Analytical biochemistry · 2024

合成路线文献Synthetic-route papers

  1. Synthesis of Poly (2-hydroxyethyl ethyleneimine) and Its Mucoadhesive Film Formulations When Blended with Chitosan for Buccal Delivery of Haloperidol
    Soradech S, Williams AC, Khutoryanskiy VV · Macromolecular bioscience · 2025
  2. Design, Synthesis, and Cytotoxic Assessment of New Haloperidol Analogues as Potential Anticancer Compounds Targeting Sigma Receptors
    Zampieri D, Romano M, Fortuna S, et al. · Molecules (Basel, Switzerland) · 2024
  3. Synthesis and Pharmacological Characterization of a Difluorinated Analogue of Reduced Haloperidol as a Sigma-1 Receptor Ligand
    Gao RD, Taylor M, McInnis T, et al. · ACS chemical neuroscience · 2023

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

氟哌啶醇 杂质谱研究要点Haloperidol — impurity profiling notes

下面这些是拿到 氟哌啶醇 的 33 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 33 impurity entries for Haloperidol, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances